Revance’s leadership is committed to setting the new standard in healthcare and has deep experience commercializing products in highly competitive markets. As a group, we represent more than a century of experience launching innovative products that change people’s lives. We believe in leaving bureaucracy behind and value speed, authenticity, audacity, grit and empathy.
For customer service, product information, new accounts or adverse events call: 877-3REV-NOW
1222 Demonbreun St
20th Floor
Nashville, TN 37203
Mark J. Foley is the CEO of Revance Therapeutics and has served as a member of the Company’s board of directors since September 2017.
Previously, Mr. Foley was Chairman, President and CEO of ZELTIQ Aesthetics (ZLTQ). During his tenure, he led ZELTIQ’s growth from $68 million in annual revenue in 2012 to over $350 million in 2016, resulting in an appreciation of the Company’s stock of greater than tenfold and acquisition by Allergan (AGN) in April of 2017 for $2.5B. Mr. Foley also served as a Managing Director of RWI Ventures, a venture capital firm focused on life sciences, networking, semiconductor and software investments, from 2004 to 2018.
Mr. Foley has over 25 years of experience in the health care field, having served in a variety of senior operating roles in both large public companies and venture-backed startups, including U.S. Surgical Corporation, Guidant Corporation, Devices for Vascular Intervention (acquired by Eli Lilly), Perclose (acquired by Abbott) and Ventrica (acquired by Medtronic), where he was the founder and CEO. Also, he has partnered with a number of entrepreneurs to assist with the formation and capitalization of new health care companies while also serving as a Senior Advisor, Executive Chairman, interim CEO and board member to a number of medical device companies.
Mr. Foley currently serves on the board of directors for Glaukos Corp., (GKOS), an ophthalmic medical technology and pharmaceutical company and has served on the board of directors for SI-BONE, a medical device company. He also co-chairs the Aesthetics Innovation Summit and was chairman of Arrinex up and until its acquisition by Stryker in the spring of 2019. Mr. Foley received his BA from the University of Notre Dame and is a named inventor on 17 patent applications.
Tobin C. Schilke joined Revance as Chief Financial Officer in November of 2018. He brings more than 20 years’ experience in the global biopharma arena, raising capital, completing mergers and acquisitions (M&A) and providing financial leadership in support of commercial enterprises. From 2016 to 2018 Mr. Schilke served as Chief Financial Officer at Achaogen, Inc., where he raised more than $300 million in capital and built teams and capabilities in financial planning and analysis (FP&A), accounting, procurement, IT and facilities management. Previously, he spent 13 years at Roche/Genentech in a variety of finance and operational roles including CFO of Roche Products Limited in the United Kingdom, Director of Commercial FP&A for Genentech’s BioOncology business, and M&A project manager for a number of successful acquisitions, restructurings, and business development initiatives. Mr. Schilke holds a B.S. in Chemical Engineering from Lafayette College, M.S. in Chemical Engineering from University of California, Berkeley, and an M.B.A. from Cornell University.
Erica Jordan is Chief Commercial Officer, Aesthetics of Revance, leading commercial activities including commercial strategy, sales operations, and marketing, branding, loyalty and engagement.
Mrs. Jordan joined Revance in 2023 as Senior Vice President, Commercial, bringing 25 years of marketing, sales management, commercial strategy, commercial operations and management experience at leading global healthcare companies. Prior to joining Revance, she served as President of the Metrex division at Envista Holdings, where she developed and executed a successful commercial strategy and implemented operational efficiencies to support double-digital growth. Erica has held several leadership roles in marketing, commercial and operational leadership roles at Phillips Healthcare, Fujifilm Medical Systems, Siemens Medical Solutions, and GE Healthcare. In these roles, Erica has successfully launched multiple products, enabled significant market growth, and transformed organizations for growth.
Erica holds a B.S. in Marketing and Finance from the University of Wisconsin, Milwaukee.
Dwight O. Moxie joined Revance in 2020 as Corporate Secretary to the Board and as Senior Vice President, General Counsel & Corporate Secretary on the Senior Executive Team. Mr. Moxie leads all legal, governance, and compliance initiatives for Revance.
Mr. Moxie brings extensive legal experience in the biopharma and healthcare sectors, advising and supporting companies developing and commercializing novel drugs. Prior to Revance, he served as the Vice President, Deputy General Counsel at Ultragenyx where he oversaw commercial operations, litigation, research & development and regulatory matters. In this position, Mr. Moxie advised on pharmaceutical education and product marketing activities, including DTC advertisements, improved review systems to support product launches and counseled on matters including clinical trials, labeling and more. Prior to Ultragenyx, he served in various legal counsel positions at Allergan and GlaxoSmithKline.
Mr. Moxie holds a J.D. degree from Howard University School of Law and a Bachelor of Arts in Social Science from Florida State University.
Amie Krause joined Revance in March 2023 as Chief People Officer, overseeing human resources and people functions, including culture initiatives, employee relations, total rewards, diversity and inclusion, leadership development, talent acquisition, as well as corporate affairs.
Amie has over 25 years of experience in the biotech industry as a senior human resources leader. Prior to joining Revance, she was the SVP and Chief People Officer at Atara Biotherapeutics in Thousand Oaks, CA where she led people strategies, company growth, culture and employee development. Prior to Atara, Amie worked for Amgen in a number of human resources roles of increasing responsibility, including her role as Global HR Lead, Organizational Effectiveness during which she served as the Human Resources Leader for Amgen’s global commercial operations covering the Americas, Europe, Asia, and the Middle East. Prior to Amgen, Amie held multiple Talent Acquisition roles, in the services, and gaming industries.
Amie is a professor at California Lutheran University, School of Business and teaches part of their MBA curriculum. She has served in Civic roles and has been a guest lecturer and speaker for various conferences including the Healthcare Businesswomen’s Association. Amie resides in Nashville with her husband Michael. Outside of work Amie enjoys movies, nature hikes, working out, and spending time with friends and family. Amie holds both a B.S. in Business Management and an MBA in Organizational Management from California Lutheran University.
David A. Hollander, M.D., M.B.A., joined Revance in October 2022 as Chief Medical Officer, overseeing clinical development, data science, medical affairs, scientific innovation, pharmacovigilance and regulatory affairs.
Dr. Hollander brings over 20 years of experience in the global biotech and pharma industry, spanning the entire drug development life cycle. Prior to joining Revance, he was the Chief Research & Development Officer at Aerie Pharmaceuticals, where he directed preclinical research and clinical development in the U.S., Europe and Japan, and led the company’s medical affairs, regulatory and quality organizations. Previously, he was the Chief Medical Officer at Ora, Inc., where he oversaw medical operations across pharmaceutical and device clinical development, preclinical studies, as well as research and development into new regulatory endpoints. Dr. Hollander began his industry career at Allergan, Inc., where he spent a decade serving in roles of increasing responsibility, including Vice President, Global Therapeutic Area Head in Clinical Development for Anterior Segment and Consumer Eye Care. Dr. Hollander currently serves as a Board Member for Kiora Pharmaceuticals and the Arnold & Mabel Beckman Foundation.
Dr. Hollander received his B.S. in chemistry with honors and distinction from Stanford University, earned his medical degree at the University of Pennsylvania School of Medicine, and obtained an M.B.A. in Health Care Management from the Wharton School. He completed his residency in ophthalmology at the University of California, San Francisco, and a Heed Fellowship in Cornea, External Disease, and Refractive Surgery at the Jules Stein Eye Institute, University of California, Los Angeles.
